Ability Pharma Seeks €6 Million to Advance its Pancreatic Cancer Trial

Ability Pharma continues to seek capital to advance the cure for cancer. The Spanish biopharmaceutical company has opened a round of financing of €6 million to advance to phase III of its pancreatic cancer trial, according to Carles Domènech, CEO of Ability Pharma.

Of the €6 million, the company based in Cerdanyola del Vallès (Barcelona) has already guaranteed three million euros, an amount that comes from the current partners, the Center for Technological Development and Innovation (Cdti), and other investors. In addition, the European Innovation Council (EIC) will also participate in this round, which will contribute up to a maximum of €1.9 million.

The company is currently in phase IIB of its trial for pancreatic cancer and has a large, closed group of people participating in Spain, France, the United States, and Israel.

The next step for Ability Pharma is to have internal results in September 2023 and transform the trial from phase IIB to the pivotal phase, that is, to have a clinical study that forms the basis of the application to the health authorities for the approval of a drug. , in this case, both the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA).

Read more about Ability Pharma and why the company needs funds, and find the latest business news of the day with the Born2Invest mobile app.

Ability Pharma wants to take its pancreatic cancer trial to the pivotal phase

Having pancreatic cancer results available could place Ability Pharma in a product license agreement situation with a pharmaceutical multinational, an operation whose value would range between forty million euros and fifty million euros, according to Domènech.

On the other hand, the company maintains in the standby phase the results of its indications for endometrial cancer and squamous cell lung cancer, for which it has trials with between thirty and forty people in each case.

The company carried out a public sale operation (OPV) process at the end of 2021 to go public, even recently changing from a limited company to a public limited company, with the aim of going public. About a possible exit to Euronext, Domènech explains that the exit to the parquet will be valued in the coming months, and in the case of being carried out, the company will open a new round of around 25 million euros.

Ability Pharma will seek €25 million if it goes public

To date, the biopharmaceutical company has received around €23 million of public and private financing, of which 43% comes from equity, 23% from government aid, 12% from subsidies, 11% from its license agreement with the Chinese company SciClone and the rest of other aid.

The latest aid that the company has received corresponds to October 2022, when Ability Pharma received €2 million of non-dilutive financing from the Ministry of Science and Innovation.

Ability Pharma has closed 2022 with a turnover of €2.3 million, which translates into an increase of 53% compared to the income of 2021. For its part, the company’s assets stand at €15 million.

__

(Featured image by jarmoluk via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.